Skip to main content
PMC home page
Environmental Health Perspectives logoLink to Environmental Health Perspectives
. 2003 Jun;111(8):1037–1054. doi: 10.1289/ehp.5787

Etiology and pathogenesis of uterine leiomyomas: a review.

Gordon P Flake 1, Janet Andersen 1, Darlene Dixon 1
PMCID: PMC1241553  PMID: 12826476

Abstract

Uterine leiomyomas, or fibroids, represent a major public health problem. It is believed that these tumors develop in the majority of American women and become symptomatic in one-third of these women. They are the most frequent indication for hysterectomy in the United States. Although the initiator or initiators of fibroids are unknown, several predisposing factors have been identified, including age (late reproductive years), African-American ethnicity, nulliparity, and obesity. Nonrandom cytogenetic abnormalities have been found in about 40% of tumors examined. Estrogen and progesterone are recognized as promoters of tumor growth, and the potential role of environmental estrogens has only recently been explored. Growth factors with mitogenic activity, such as transforming growth factor- (subscript)3(/subscript), basic fibroblast growth factor, epidermal growth factor, and insulin-like growth factor-I, are elevated in fibroids and may be the effectors of estrogen and progesterone promotion. These data offer clues to the etiology and pathogenesis of this common condition, which we have analyzed and summarized in this review.

Full Text

The Full Text of this article is available as a PDF (237.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abraham S., Johnson C. L. Prevalence of severe obesity in adults in the United States. Am J Clin Nutr. 1980 Feb;33(2 Suppl):364–369. doi: 10.1093/ajcn/33.2.364. [DOI] [PubMed] [Google Scholar]
  2. Adlercreutz H., Fotsis T., Heikkinen R., Dwyer J. T., Woods M., Goldin B. R., Gorbach S. L. Excretion of the lignans enterolactone and enterodiol and of equol in omnivorous and vegetarian postmenopausal women and in women with breast cancer. Lancet. 1982 Dec 11;2(8311):1295–1299. doi: 10.1016/s0140-6736(82)91507-0. [DOI] [PubMed] [Google Scholar]
  3. Adlercreutz H., Mazur W. Phyto-oestrogens and Western diseases. Ann Med. 1997 Apr;29(2):95–120. doi: 10.3109/07853899709113696. [DOI] [PubMed] [Google Scholar]
  4. Aharoni A., Reiter A., Golan D., Paltiely Y., Sharf M. Patterns of growth of uterine leiomyomas during pregnancy. A prospective longitudinal study. Br J Obstet Gynaecol. 1988 May;95(5):510–513. doi: 10.1111/j.1471-0528.1988.tb12807.x. [DOI] [PubMed] [Google Scholar]
  5. Alam N. A., Bevan S., Churchman M., Barclay E., Barker K., Jaeger E. E., Nelson H. M., Healy E., Pembroke A. C., Friedmann P. S. Localization of a gene (MCUL1) for multiple cutaneous leiomyomata and uterine fibroids to chromosome 1q42.3-q43. Am J Hum Genet. 2001 Mar 14;68(5):1264–1269. doi: 10.1086/320124. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Albala J. S., Thelen M. P., Prange C., Fan W., Christensen M., Thompson L. H., Lennon G. G. Identification of a novel human RAD51 homolog, RAD51B. Genomics. 1997 Dec 15;46(3):476–479. doi: 10.1006/geno.1997.5062. [DOI] [PubMed] [Google Scholar]
  7. Amant F., Debiec-Rychter M., Schoenmakers E. F., Hagemeijer-Hausman A., Vergote I. Cumulative dosage effect of a RAD51L1/HMGA2 fusion and RAD51L1 loss in a case of pseudo-Meigs' syndrome. Genes Chromosomes Cancer. 2001 Dec;32(4):324–329. doi: 10.1002/gcc.1197. [DOI] [PubMed] [Google Scholar]
  8. Anania C. A., Stewart E. A., Quade B. J., Hill J. A., Nowak R. A. Expression of the fibroblast growth factor receptor in women with leiomyomas and abnormal uterine bleeding. Mol Hum Reprod. 1997 Aug;3(8):685–691. doi: 10.1093/molehr/3.8.685. [DOI] [PubMed] [Google Scholar]
  9. Andersen J., Barbieri R. L. Abnormal gene expression in uterine leiomyomas. J Soc Gynecol Investig. 1995 Sep-Oct;2(5):663–672. doi: 10.1016/1071-5576(95)00021-6. [DOI] [PubMed] [Google Scholar]
  10. Andersen J., DyReyes V. M., Barbieri R. L., Coachman D. M., Miksicek R. J. Leiomyoma primary cultures have elevated transcriptional response to estrogen compared with autologous myometrial cultures. J Soc Gynecol Investig. 1995 May-Jun;2(3):542–551. doi: 10.1016/1071-5576(94)00053-4. [DOI] [PubMed] [Google Scholar]
  11. Andersen J. Factors in fibroid growth. Baillieres Clin Obstet Gynaecol. 1998 Jun;12(2):225–243. [PubMed] [Google Scholar]
  12. Arici A., Sozen I. Transforming growth factor-beta3 is expressed at high levels in leiomyoma where it stimulates fibronectin expression and cell proliferation. Fertil Steril. 2000 May;73(5):1006–1011. doi: 10.1016/s0015-0282(00)00418-0. [DOI] [PubMed] [Google Scholar]
  13. Barbieri R. L., McShane P. M., Ryan K. J. Constituents of cigarette smoke inhibit human granulosa cell aromatase. Fertil Steril. 1986 Aug;46(2):232–236. [PubMed] [Google Scholar]
  14. Baron J. A., La Vecchia C., Levi F. The antiestrogenic effect of cigarette smoking in women. Am J Obstet Gynecol. 1990 Feb;162(2):502–514. doi: 10.1016/0002-9378(90)90420-c. [DOI] [PubMed] [Google Scholar]
  15. Battegay E. J., Raines E. W., Seifert R. A., Bowen-Pope D. F., Ross R. TGF-beta induces bimodal proliferation of connective tissue cells via complex control of an autocrine PDGF loop. Cell. 1990 Nov 2;63(3):515–524. doi: 10.1016/0092-8674(90)90448-n. [DOI] [PubMed] [Google Scholar]
  16. Benassayag C., Leroy M. J., Rigourd V., Robert B., Honoré J. C., Mignot T. M., Vacher-Lavenu M. C., Chapron C., Ferré F. Estrogen receptors (ERalpha/ERbeta) in normal and pathological growth of the human myometrium: pregnancy and leiomyoma. Am J Physiol. 1999 Jun;276(6 Pt 1):E1112–E1118. doi: 10.1152/ajpendo.1999.276.6.E1112. [DOI] [PubMed] [Google Scholar]
  17. Bigsby R. M., Caperell-Grant A., Madhukar B. V. Xenobiotics released from fat during fasting produce estrogenic effects in ovariectomized mice. Cancer Res. 1997 Mar 1;57(5):865–869. [PubMed] [Google Scholar]
  18. Boehm K. D., Daimon M., Gorodeski I. G., Sheean L. A., Utian W. H., Ilan J. Expression of the insulin-like and platelet-derived growth factor genes in human uterine tissues. Mol Reprod Dev. 1990 Oct;27(2):93–101. doi: 10.1002/mrd.1080270203. [DOI] [PubMed] [Google Scholar]
  19. Boudouris O., Ferrand S., Guillet J. L., Madelenat P. Effets paradoxaux du tamoxifène sur l'utérus de la femme. A propos de sept cas de myomes apparus sous traitement anti-estrogénique. J Gynecol Obstet Biol Reprod (Paris) 1989;18(3):372–378. [PubMed] [Google Scholar]
  20. Brandon D. D., Bethea C. L., Strawn E. Y., Novy M. J., Burry K. A., Harrington M. S., Erickson T. E., Warner C., Keenan E. J., Clinton G. M. Progesterone receptor messenger ribonucleic acid and protein are overexpressed in human uterine leiomyomas. Am J Obstet Gynecol. 1993 Jul;169(1):78–85. doi: 10.1016/0002-9378(93)90135-6. [DOI] [PubMed] [Google Scholar]
  21. Brandon D. D., Erickson T. E., Keenan E. J., Strawn E. Y., Novy M. J., Burry K. A., Warner C., Clinton G. M. Estrogen receptor gene expression in human uterine leiomyomata. J Clin Endocrinol Metab. 1995 Jun;80(6):1876–1881. doi: 10.1210/jcem.80.6.7775635. [DOI] [PubMed] [Google Scholar]
  22. Brosens I., Deprest J., Dal Cin P., Van den Berghe H. Clinical significance of cytogenetic abnormalities in uterine myomas. Fertil Steril. 1998 Feb;69(2):232–235. doi: 10.1016/s0015-0282(97)00472-x. [DOI] [PubMed] [Google Scholar]
  23. Brown L. F., Detmar M., Tognazzi K., Abu-Jawdeh G., Iruela-Arispe M. L. Uterine smooth muscle cells express functional receptors (flt-1 and KDR) for vascular permeability factor/vascular endothelial growth factor. Lab Invest. 1997 Feb;76(2):245–255. [PubMed] [Google Scholar]
  24. Buttram V. C., Jr Uterine leiomyomata--aetiology, symptomatology and management. Prog Clin Biol Res. 1986;225:275–296. [PubMed] [Google Scholar]
  25. Büchi K. A., Keller P. J. Cytoplasmic progestin receptors in myomal and myometrial tissues. Concentrations and hormonal dependency. Acta Obstet Gynecol Scand. 1983;62(5):487–492. doi: 10.3109/00016348309154224. [DOI] [PubMed] [Google Scholar]
  26. Carr B. R., Marshburn P. B., Weatherall P. T., Bradshaw K. D., Breslau N. A., Byrd W., Roark M., Steinkampf M. P. An evaluation of the effect of gonadotropin-releasing hormone analogs and medroxyprogesterone acetate on uterine leiomyomata volume by magnetic resonance imaging: a prospective, randomized, double blind, placebo-controlled, crossover trial. J Clin Endocrinol Metab. 1993 May;76(5):1217–1223. doi: 10.1210/jcem.76.5.8496313. [DOI] [PubMed] [Google Scholar]
  27. Cassidenti D. L., Pike M. C., Vijod A. G., Stanczyk F. Z., Lobo R. A. A reevaluation of estrogen status in postmenopausal women who smoke. Am J Obstet Gynecol. 1992 May;166(5):1444–1448. doi: 10.1016/0002-9378(92)91617-j. [DOI] [PubMed] [Google Scholar]
  28. Cecil H. C., Bitman J., Harris S. J. Estrogenicity of o,p'-DDT in rats. J Agric Food Chem. 1971 Jan-Feb;19(1):61–65. doi: 10.1021/jf60173a049. [DOI] [PubMed] [Google Scholar]
  29. Chandrasekhar Y., Heiner J., Osuamkpe C., Nagamani M. Insulin-like growth factor I and II binding in human myometrium and leiomyomas. Am J Obstet Gynecol. 1992 Jan;166(1 Pt 1):64–69. doi: 10.1016/0002-9378(92)91831-t. [DOI] [PubMed] [Google Scholar]
  30. Charnock-Jones D. S., Sharkey A. M., Rajput-Williams J., Burch D., Schofield J. P., Fountain S. A., Boocock C. A., Smith S. K. Identification and localization of alternately spliced mRNAs for vascular endothelial growth factor in human uterus and estrogen regulation in endometrial carcinoma cell lines. Biol Reprod. 1993 May;48(5):1120–1128. doi: 10.1095/biolreprod48.5.1120. [DOI] [PubMed] [Google Scholar]
  31. Chegini N., Rao C. V., Wakim N., Sanfilippo J. Binding of 125I-epidermal growth factor in human uterus. Cell Tissue Res. 1986;246(3):543–548. doi: 10.1007/BF00215194. [DOI] [PubMed] [Google Scholar]
  32. Chegini N., Zhao Y., Williams R. S., Flanders K. C. Human uterine tissue throughout the menstrual cycle expresses transforming growth factor-beta 1 (TGF beta 1), TGF beta 2, TGF beta 3, and TGF beta type II receptor messenger ribonucleic acid and protein and contains [125I]TGF beta 1-binding sites. Endocrinology. 1994 Jul;135(1):439–449. doi: 10.1210/endo.135.1.8013382. [DOI] [PubMed] [Google Scholar]
  33. Chen L., Lindner H. R., Lancet M. Mitogenic action of oestradiol-17 beta on human myometrial and endometrial cells in long-term tissue cultures. J Endocrinol. 1973 Oct;59(1):87–97. doi: 10.1677/joe.0.0590087. [DOI] [PubMed] [Google Scholar]
  34. Chiaffarino F., Parazzini F., La Vecchia C., Chatenoud L., Di Cintio E., Marsico S. Diet and uterine myomas. Obstet Gynecol. 1999 Sep;94(3):395–398. doi: 10.1016/s0029-7844(99)00305-1. [DOI] [PubMed] [Google Scholar]
  35. Cohick W. S., Clemmons D. R. The insulin-like growth factors. Annu Rev Physiol. 1993;55:131–153. doi: 10.1146/annurev.ph.55.030193.001023. [DOI] [PubMed] [Google Scholar]
  36. Colacurci N., De Franciscis P., Cobellis L., Nazzaro G., De Placido G. Effects of hormone replacement therapy on postmenopausal uterine myoma. Maturitas. 2000 May 29;35(2):167–173. doi: 10.1016/s0378-5122(00)00115-8. [DOI] [PubMed] [Google Scholar]
  37. Colgan T. J., Pendergast S., LeBlanc M. The histopathology of uterine leiomyomas following treatment with gonadotropin-releasing hormone analogues. Hum Pathol. 1993 Oct;24(10):1073–1077. doi: 10.1016/0046-8177(93)90186-k. [DOI] [PubMed] [Google Scholar]
  38. Cramer S. F., Horiszny J. A., Leppert P. Epidemiology of uterine leiomyomas. With an etiologic hypothesis. J Reprod Med. 1995 Aug;40(8):595–600. [PubMed] [Google Scholar]
  39. Cramer S. F., Patel A. The frequency of uterine leiomyomas. Am J Clin Pathol. 1990 Oct;94(4):435–438. doi: 10.1093/ajcp/94.4.435. [DOI] [PubMed] [Google Scholar]
  40. Cullinan-Bove K., Koos R. D. Vascular endothelial growth factor/vascular permeability factor expression in the rat uterus: rapid stimulation by estrogen correlates with estrogen-induced increases in uterine capillary permeability and growth. Endocrinology. 1993 Aug;133(2):829–837. doi: 10.1210/endo.133.2.8344219. [DOI] [PubMed] [Google Scholar]
  41. Daly D. C., Walters C. A., Prior J. C., Kuslis S. T., Chapitis J., Andreoli J., Riddick D. H. Prolactin production from proliferative phase leiomyoma. Am J Obstet Gynecol. 1984 Apr 15;148(8):1059–1063. doi: 10.1016/s0002-9378(84)90445-9. [DOI] [PubMed] [Google Scholar]
  42. Daniel M., Martin A. D., Faiman C. Sex hormones and adipose tissue distribution in premenopausal cigarette smokers. Int J Obes Relat Metab Disord. 1992 Apr;16(4):245–254. [PubMed] [Google Scholar]
  43. Dawood M. Y., Khan-Dawood F. S. Plasma insulin-like growth factor-I, CA-125, estrogen, and progesterone in women with leiomyomas. Fertil Steril. 1994 Apr;61(4):617–621. doi: 10.1016/s0015-0282(16)56635-7. [DOI] [PubMed] [Google Scholar]
  44. Debodinance P. Hystérectomies pour lésions bénignes sur utérus non prolabé: Epidémiologie et suites opératoires dans le Nord de la France. J Gynecol Obstet Biol Reprod (Paris) 2001 Apr;30(2):151–159. [PubMed] [Google Scholar]
  45. Deligdisch L. Hormonal pathology of the endometrium. Mod Pathol. 2000 Mar;13(3):285–294. doi: 10.1038/modpathol.3880050. [DOI] [PubMed] [Google Scholar]
  46. Dilts P. V., Jr, Hopkins M. P., Chang A. E., Cody R. L. Rapid growth of leiomyoma in patient receiving tamoxifen. Am J Obstet Gynecol. 1992 Jan;166(1 Pt 1):167–168. doi: 10.1016/0002-9378(92)91854-4. [DOI] [PubMed] [Google Scholar]
  47. Dixon D., He H., Haseman J. K. Immunohistochemical localization of growth factors and their receptors in uterine leiomyomas and matched myometrium. Environ Health Perspect. 2000 Oct;108 (Suppl 5):795–802. doi: 10.1289/ehp.00108s5795. [DOI] [PubMed] [Google Scholar]
  48. Dixon Darlene, Flake Gordon P., Moore Alicia B., He Hong, Haseman Joseph K., Risinger John I., Lancaster Johnathan M., Berchuck Andrew, Barrett J. Carl, Robboy Stanley J. Cell proliferation and apoptosis in human uterine leiomyomas and myometria. Virchows Arch. 2002 Mar 23;441(1):53–62. doi: 10.1007/s00428-001-0568-7. [DOI] [PubMed] [Google Scholar]
  49. Eiletz J., Genz T., Pollow K., Schmidt-Gollwitzer M. Sex steroid levels in serum, myometrium, and fibromyomata in correlation with cytoplasmic receptors and 17 beta-HSD activity in different age-groups and phases of the menstrual cycle. Arch Gynecol. 1980 Jan;229(1):13–28. doi: 10.1007/BF02109824. [DOI] [PubMed] [Google Scholar]
  50. Englund K., Blanck A., Gustavsson I., Lundkvist U., Sjöblom P., Norgren A., Lindblom B. Sex steroid receptors in human myometrium and fibroids: changes during the menstrual cycle and gonadotropin-releasing hormone treatment. J Clin Endocrinol Metab. 1998 Nov;83(11):4092–4096. doi: 10.1210/jcem.83.11.5287. [DOI] [PubMed] [Google Scholar]
  51. Enmark E., Pelto-Huikko M., Grandien K., Lagercrantz S., Lagercrantz J., Fried G., Nordenskjöld M., Gustafsson J. A. Human estrogen receptor beta-gene structure, chromosomal localization, and expression pattern. J Clin Endocrinol Metab. 1997 Dec;82(12):4258–4265. doi: 10.1210/jcem.82.12.4470. [DOI] [PubMed] [Google Scholar]
  52. Ezem B. U., Otubu J. A. Hysterectomy in the Hausa/Fulani population in Nigeria. Int J Gynaecol Obstet. 1981 Apr;19(2):145–148. doi: 10.1016/0020-7292(81)90054-0. [DOI] [PubMed] [Google Scholar]
  53. FISHER W. C., HELWIG E. B. LEIOMYOMAS OF THE SKIN. Arch Dermatol. 1963 Nov;88:510–520. doi: 10.1001/archderm.1963.01590230018002. [DOI] [PubMed] [Google Scholar]
  54. Fayed Y. M., Tsibris J. C., Langenberg P. W., Robertson A. L., Jr Human uterine leiomyoma cells: binding and growth responses to epidermal growth factor, platelet-derived growth factor, and insulin. Lab Invest. 1989 Jan;60(1):30–37. [PubMed] [Google Scholar]
  55. Fedele L., Bianchi S., Raffaelli R., Zanconato G. A randomized study of the effects of tibolone and transdermal estrogen replacement therapy in postmenopausal women with uterine myomas. Eur J Obstet Gynecol Reprod Biol. 2000 Jan;88(1):91–94. doi: 10.1016/s0301-2115(99)00115-3. [DOI] [PubMed] [Google Scholar]
  56. Ferrara N., Houck K., Jakeman L., Leung D. W. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev. 1992 Feb;13(1):18–32. doi: 10.1210/edrv-13-1-18. [DOI] [PubMed] [Google Scholar]
  57. Fey M. F., Peter H. J., Hinds H. L., Zimmermann A., Liechti-Gallati S., Gerber H., Studer H., Tobler A. Clonal analysis of human tumors with M27 beta, a highly informative polymorphic X chromosomal probe. J Clin Invest. 1992 May;89(5):1438–1444. doi: 10.1172/JCI115733. [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Folkerd E. J., Newton C. J., Davidson K., Anderson M. C., James V. H. Aromatase activity in uterine leiomyomata. J Steroid Biochem. 1984 May;20(5):1195–1200. doi: 10.1016/0022-4731(84)90366-2. [DOI] [PubMed] [Google Scholar]
  59. Fraser H. M. LHRH analogues: their clinical physiology and delivery systems. Baillieres Clin Obstet Gynaecol. 1988 Sep;2(3):639–658. doi: 10.1016/s0950-3552(88)80050-6. [DOI] [PubMed] [Google Scholar]
  60. Friedman A. J., Barbieri R. L., Doubilet P. M., Fine C., Schiff I. A randomized, double-blind trial of a gonadotropin releasing-hormone agonist (leuprolide) with or without medroxyprogesterone acetate in the treatment of leiomyomata uteri. Fertil Steril. 1988 Mar;49(3):404–409. doi: 10.1016/s0015-0282(16)59763-5. [DOI] [PubMed] [Google Scholar]
  61. Friedman A. J., Harrison-Atlas D., Barbieri R. L., Benacerraf B., Gleason R., Schiff I. A randomized, placebo-controlled, double-blind study evaluating the efficacy of leuprolide acetate depot in the treatment of uterine leiomyomata. Fertil Steril. 1989 Feb;51(2):251–256. doi: 10.1016/s0015-0282(16)60486-7. [DOI] [PubMed] [Google Scholar]
  62. Friedman A. J., Lobel S. M., Rein M. S., Barbieri R. L. Efficacy and safety considerations in women with uterine leiomyomas treated with gonadotropin-releasing hormone agonists: the estrogen threshold hypothesis. Am J Obstet Gynecol. 1990 Oct;163(4 Pt 1):1114–1119. doi: 10.1016/0002-9378(90)90667-v. [DOI] [PubMed] [Google Scholar]
  63. Frigo P., Eppel W., Asseryanis E., Sator M., Golaszewski T., Gruber D., Lang C., Huber J. The effects of hormone substitution in depot form on the uterus in a group of 50 perimenopausal women--a vaginosonographic study. Maturitas. 1995 Apr;21(3):221–225. doi: 10.1016/0378-5122(94)00893-c. [DOI] [PubMed] [Google Scholar]
  64. Frisch R. E., Wyshak G., Albright N. L., Albright T. E., Schiff I., Jones K. P., Witschi J., Shiang E., Koff E., Marguglio M. Lower prevalence of breast cancer and cancers of the reproductive system among former college athletes compared to non-athletes. Br J Cancer. 1985 Dec;52(6):885–891. doi: 10.1038/bjc.1985.273. [DOI] [PMC free article] [PubMed] [Google Scholar]
  65. Fuchs-Young R., Howe S., Hale L., Miles R., Walker C. Inhibition of estrogen-stimulated growth of uterine leiomyomas by selective estrogen receptor modulators. Mol Carcinog. 1996 Nov;17(3):151–159. doi: 10.1002/(SICI)1098-2744(199611)17:3<151::AID-MC7>3.0.CO;2-I. [DOI] [PubMed] [Google Scholar]
  66. Fujimoto J., Hori M., Ichigo S., Tamaya T. Ovarian steroids regulate the expression of basic fibroblast growth factor and its mRNA in fibroblasts derived from uterine endometrium. Ann Clin Biochem. 1997 Jan;34(Pt 1):91–96. doi: 10.1177/000456329703400114. [DOI] [PubMed] [Google Scholar]
  67. Gambone J. C., Reiter R. C., Lench J. B., Moore J. G. The impact of a quality assurance process on the frequency and confirmation rate of hysterectomy. Am J Obstet Gynecol. 1990 Aug;163(2):545–550. doi: 10.1016/0002-9378(90)91195-i. [DOI] [PubMed] [Google Scholar]
  68. Gattas G. J., Quade B. J., Nowak R. A., Morton C. C. HMGIC expression in human adult and fetal tissues and in uterine leiomyomata. Genes Chromosomes Cancer. 1999 Aug;25(4):316–322. [PubMed] [Google Scholar]
  69. Ginsburg J., Prelevic G. M. Lack of significant hormonal effects and controlled trials of phyto-oestrogens. Lancet. 2000 Jan 15;355(9199):163–164. doi: 10.1016/S0140-6736(99)00428-6. [DOI] [PubMed] [Google Scholar]
  70. Giudice L. C., Irwin J. C., Dsupin B. A., Pannier E. M., Jin I. H., Vu T. H., Hoffman A. R. Insulin-like growth factor (IGF), IGF binding protein (IGFBP), and IGF receptor gene expression and IGFBP synthesis in human uterine leiomyomata. Hum Reprod. 1993 Nov;8(11):1796–1806. doi: 10.1093/oxfordjournals.humrep.a137937. [DOI] [PubMed] [Google Scholar]
  71. Glass A. R. Endocrine aspects of obesity. Med Clin North Am. 1989 Jan;73(1):139–160. doi: 10.1016/s0025-7125(16)30696-4. [DOI] [PubMed] [Google Scholar]
  72. Gloudemans T., Prinsen I., Van Unnik J. A., Lips C. J., Den Otter W., Sussenbach J. S. Insulin-like growth factor gene expression in human smooth muscle tumors. Cancer Res. 1990 Oct 15;50(20):6689–6695. [PubMed] [Google Scholar]
  73. Goldin B. R., Adlercreutz H., Gorbach S. L., Warram J. H., Dwyer J. T., Swenson L., Woods M. N. Estrogen excretion patterns and plasma levels in vegetarian and omnivorous women. N Engl J Med. 1982 Dec 16;307(25):1542–1547. doi: 10.1056/NEJM198212163072502. [DOI] [PubMed] [Google Scholar]
  74. Goldzieher J. W., Maqueo M., Ricaud L., Aguilar J. A., Canales E. Induction of degenerative changes in uterine myomas by high-dosage progestin therapy. Am J Obstet Gynecol. 1966 Dec 15;96(8):1078–1087. doi: 10.1016/0002-9378(66)90516-3. [DOI] [PubMed] [Google Scholar]
  75. Gorbach S. L., Goldin B. R. Diet and the excretion and enterohepatic cycling of estrogens. Prev Med. 1987 Jul;16(4):525–531. doi: 10.1016/0091-7435(87)90067-3. [DOI] [PubMed] [Google Scholar]
  76. Goto F., Goto K., Weindel K., Folkman J. Synergistic effects of vascular endothelial growth factor and basic fibroblast growth factor on the proliferation and cord formation of bovine capillary endothelial cells within collagen gels. Lab Invest. 1993 Nov;69(5):508–517. [PubMed] [Google Scholar]
  77. Gross K. L., Morton C. C. Genetics and the development of fibroids. Clin Obstet Gynecol. 2001 Jun;44(2):335–349. doi: 10.1097/00003081-200106000-00020. [DOI] [PubMed] [Google Scholar]
  78. Hall J. M., Couse J. F., Korach K. S. The multifaceted mechanisms of estradiol and estrogen receptor signaling. J Biol Chem. 2001 Jul 17;276(40):36869–36872. doi: 10.1074/jbc.R100029200. [DOI] [PubMed] [Google Scholar]
  79. Haney A. F. Clinical decision making regarding leiomyomata: what we need in the next millenium. Environ Health Perspect. 2000 Oct;108 (Suppl 5):835–839. doi: 10.1289/ehp.00108s5835. [DOI] [PubMed] [Google Scholar]
  80. Harrison-Woolrych M. L., Charnock-Jones D. S., Smith S. K. Quantification of messenger ribonucleic acid for epidermal growth factor in human myometrium and leiomyomata using reverse transcriptase polymerase chain reaction. J Clin Endocrinol Metab. 1994 May;78(5):1179–1184. doi: 10.1210/jcem.78.5.8175976. [DOI] [PubMed] [Google Scholar]
  81. Harrison-Woolrych M. L., Sharkey A. M., Charnock-Jones D. S., Smith S. K. Localization and quantification of vascular endothelial growth factor messenger ribonucleic acid in human myometrium and leiomyomata. J Clin Endocrinol Metab. 1995 Jun;80(6):1853–1858. doi: 10.1210/jcem.80.6.7775632. [DOI] [PubMed] [Google Scholar]
  82. Hashimoto K., Azuma C., Kamiura S., Kimura T., Nobunaga T., Kanai T., Sawada M., Noguchi S., Saji F. Clonal determination of uterine leiomyomas by analyzing differential inactivation of the X-chromosome-linked phosphoglycerokinase gene. Gynecol Obstet Invest. 1995;40(3):204–208. doi: 10.1159/000292336. [DOI] [PubMed] [Google Scholar]
  83. Havre P. A., Rice M. C., Noe M., Kmiec E. B. The human REC2/RAD51B gene acts as a DNA damage sensor by inducing G1 delay and hypersensitivity to ultraviolet irradiation. Cancer Res. 1998 Oct 15;58(20):4733–4739. [PubMed] [Google Scholar]
  84. Havre P. A., Rice M., Ramos R., Kmiec E. B. HsRec2/Rad51L1, a protein influencing cell cycle progression, has protein kinase activity. Exp Cell Res. 2000 Jan 10;254(1):33–44. doi: 10.1006/excr.1999.4725. [DOI] [PubMed] [Google Scholar]
  85. Higashijima T., Kataoka A., Nishida T., Yakushiji M. Gonadotropin-releasing hormone agonist therapy induces apoptosis in uterine leiomyoma. Eur J Obstet Gynecol Reprod Biol. 1996 Sep;68(1-2):169–173. doi: 10.1016/0301-2115(96)02504-3. [DOI] [PubMed] [Google Scholar]
  86. Hodges L. C., Bergerson J. S., Hunter D. S., Walker C. L. Estrogenic effects of organochlorine pesticides on uterine leiomyoma cells in vitro. Toxicol Sci. 2000 Apr;54(2):355–364. doi: 10.1093/toxsci/54.2.355. [DOI] [PubMed] [Google Scholar]
  87. Hofmann G. E., Rao C. V., Barrows G. H., Schultz G. S., Sanfilippo J. S. Binding sites for epidermal growth factor in human uterine tissues and leiomyomas. J Clin Endocrinol Metab. 1984 May;58(5):880–884. doi: 10.1210/jcem-58-5-880. [DOI] [PubMed] [Google Scholar]
  88. Houston K. D., Hunter D. S., Hodges L. C., Walker C. L. Uterine leiomyomas: mechanisms of tumorigenesis. Toxicol Pathol. 2001 Jan-Feb;29(1):100–104. doi: 10.1080/019262301301418900. [DOI] [PubMed] [Google Scholar]
  89. Hsueh A. J., Peck E. J., Jr, clark J. H. Progesterone antagonism of the oestrogen receptor and oestrogen-induced uterine growth. Nature. 1975 Mar 27;254(5498):337–339. doi: 10.1038/254337a0. [DOI] [PubMed] [Google Scholar]
  90. Hung T. T., Gibbons W. E. Evaluation of androgen antagonism of estrogen effect by dihydrotestosterone. J Steroid Biochem. 1983 Oct;19(4):1513–1520. doi: 10.1016/0022-4731(83)91128-7. [DOI] [PubMed] [Google Scholar]
  91. Hunter D. S., Hodges L. C., Eagon P. K., Vonier P. M., Fuchs-Young R., Bergerson J. S., Walker C. L. Influence of exogenous estrogen receptor ligands on uterine leiomyoma: evidence from an in vitro/in vivo animal model for uterine fibroids. Environ Health Perspect. 2000 Oct;108 (Suppl 5):829–834. doi: 10.1289/ehp.00108s5829. [DOI] [PubMed] [Google Scholar]
  92. Hyder S. M., Huang J. C., Nawaz Z., Boettger-Tong H., Mäkelä S., Chiappetta C., Stancel G. M. Regulation of vascular endothelial growth factor expression by estrogens and progestins. Environ Health Perspect. 2000 Oct;108 (Suppl 5):785–790. doi: 10.1289/ehp.00108s5785. [DOI] [PubMed] [Google Scholar]
  93. Hyder S. M., Stancel G. M., Chiappetta C., Murthy L., Boettger-Tong H. L., Makela S. Uterine expression of vascular endothelial growth factor is increased by estradiol and tamoxifen. Cancer Res. 1996 Sep 1;56(17):3954–3960. [PubMed] [Google Scholar]
  94. Höppener J. W., Mosselman S., Roholl P. J., Lambrechts C., Slebos R. J., de Pagter-Holthuizen P., Lips C. J., Jansz H. S., Sussenbach J. S. Expression of insulin-like growth factor-I and -II genes in human smooth muscle tumours. EMBO J. 1988 May;7(5):1379–1385. doi: 10.1002/j.1460-2075.1988.tb02954.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  95. Ingraham S. E., Lynch R. A., Kathiresan S., Buckler A. J., Menon A. G. hREC2, a RAD51-like gene, is disrupted by t(12;14) (q15;q24.1) in a uterine leiomyoma. Cancer Genet Cytogenet. 1999 Nov;115(1):56–61. doi: 10.1016/s0165-4608(99)00070-9. [DOI] [PubMed] [Google Scholar]
  96. Jonca F., Ortéga N., Gleizes P. E., Bertrand N., Plouët J. Cell release of bioactive fibroblast growth factor 2 by exon 6-encoded sequence of vascular endothelial growth factor. J Biol Chem. 1997 Sep 26;272(39):24203–24209. doi: 10.1074/jbc.272.39.24203. [DOI] [PubMed] [Google Scholar]
  97. Jänne O., Kontula K., Luukkainen T., Vihko R. Oestrogen-induced progesterone receptor in human uterus. J Steroid Biochem. 1975 Mar-Apr;6(3-4):501–509. doi: 10.1016/0022-4731(75)90179-x. [DOI] [PubMed] [Google Scholar]
  98. Kang J., Baxi L., Heller D. Tamoxifen-induced growth of leiomyomas. A case report. J Reprod Med. 1996 Feb;41(2):119–120. [PubMed] [Google Scholar]
  99. Katz V. L., Dotters D. J., Droegemeuller W. Complications of uterine leiomyomas in pregnancy. Obstet Gynecol. 1989 Apr;73(4):593–596. [PubMed] [Google Scholar]
  100. Katzenellenbogen B. S. Dynamics of steroid hormone receptor action. Annu Rev Physiol. 1980;42:17–35. doi: 10.1146/annurev.ph.42.030180.000313. [DOI] [PubMed] [Google Scholar]
  101. Kawaguchi K., Fujii S., Konishi I., Iwai T., Nanbu Y., Nonogaki H., Ishikawa Y., Mori T. Immunohistochemical analysis of oestrogen receptors, progesterone receptors and Ki-67 in leiomyoma and myometrium during the menstrual cycle and pregnancy. Virchows Arch A Pathol Anat Histopathol. 1991;419(4):309–315. doi: 10.1007/BF01606522. [DOI] [PubMed] [Google Scholar]
  102. Kawaguchi K., Fujii S., Konishi I., Nanbu Y., Nonogaki H., Mori T. Mitotic activity in uterine leiomyomas during the menstrual cycle. Am J Obstet Gynecol. 1989 Mar;160(3):637–641. doi: 10.1016/s0002-9378(89)80046-8. [DOI] [PubMed] [Google Scholar]
  103. Kennedy M. M., Baigrie C. F., Manek S. Tamoxifen and the endometrium: review of 102 cases and comparison with HRT-related and non-HRT-related endometrial pathology. Int J Gynecol Pathol. 1999 Apr;18(2):130–137. [PubMed] [Google Scholar]
  104. Kiuru M., Launonen V., Hietala M., Aittomäki K., Vierimaa O., Salovaara R., Arola J., Pukkala E., Sistonen P., Herva R. Familial cutaneous leiomyomatosis is a two-hit condition associated with renal cell cancer of characteristic histopathology. Am J Pathol. 2001 Sep;159(3):825–829. doi: 10.1016/S0002-9440(10)61757-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  105. Kjerulff K. H., Langenberg P., Seidman J. D., Stolley P. D., Guzinski G. M. Uterine leiomyomas. Racial differences in severity, symptoms and age at diagnosis. J Reprod Med. 1996 Jul;41(7):483–490. [PubMed] [Google Scholar]
  106. Kuiper G. G., Enmark E., Pelto-Huikko M., Nilsson S., Gustafsson J. A. Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci U S A. 1996 Jun 11;93(12):5925–5930. doi: 10.1073/pnas.93.12.5925. [DOI] [PMC free article] [PubMed] [Google Scholar]
  107. Kurbanova M. Kh, Koroleva A. G., Sergeev A. S. Genetiko-épidemiologicheskii analiz miomy matki: otsenka povtornogo riska. Genetika. 1989 Oct;25(10):1896–1898. [PubMed] [Google Scholar]
  108. Lamminen S., Rantala I., Helin H., Rorarius M., Tuimala R. Proliferative activity of human uterine leiomyoma cells as measured by automatic image analysis. Gynecol Obstet Invest. 1992;34(2):111–114. doi: 10.1159/000292738. [DOI] [PubMed] [Google Scholar]
  109. Launonen V., Vierimaa O., Kiuru M., Isola J., Roth S., Pukkala E., Sistonen P., Herva R., Aaltonen L. A. Inherited susceptibility to uterine leiomyomas and renal cell cancer. Proc Natl Acad Sci U S A. 2001 Feb 27;98(6):3387–3392. doi: 10.1073/pnas.051633798. [DOI] [PMC free article] [PubMed] [Google Scholar]
  110. Le Bouëdec G., de Latour M., Dauplat J. Myomes utérins expansifs sous tamoxifène. 11 observations. Presse Med. 1995 Nov 25;24(36):1694–1696. [PubMed] [Google Scholar]
  111. Leo L., Lanza A., Re A., Tessarolo M., Bellino R., Lauricella A., Wierdis T. Leiomyomas in patients receiving Tamoxifen. Clin Exp Obstet Gynecol. 1994;21(2):94–98. [PubMed] [Google Scholar]
  112. Lessl M., Klotzbuecher M., Schoen S., Reles A., Stöckemann K., Fuhrmann U. Comparative messenger ribonucleic acid analysis of immediate early genes and sex steroid receptors in human leiomyoma and healthy myometrium. J Clin Endocrinol Metab. 1997 Aug;82(8):2596–2600. doi: 10.1210/jcem.82.8.4141. [DOI] [PubMed] [Google Scholar]
  113. Levy B., Mukherjee T., Hirschhorn K. Molecular cytogenetic analysis of uterine leiomyoma and leiomyosarcoma by comparative genomic hybridization. Cancer Genet Cytogenet. 2000 Aug;121(1):1–8. doi: 10.1016/s0165-4608(00)00225-9. [DOI] [PubMed] [Google Scholar]
  114. Liehr J. G., Ricci M. J., Jefcoate C. R., Hannigan E. V., Hokanson J. A., Zhu B. T. 4-Hydroxylation of estradiol by human uterine myometrium and myoma microsomes: implications for the mechanism of uterine tumorigenesis. Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9220–9224. doi: 10.1073/pnas.92.20.9220. [DOI] [PMC free article] [PubMed] [Google Scholar]
  115. Ligon A. H., Morton C. C. Genetics of uterine leiomyomata. Genes Chromosomes Cancer. 2000 Jul;28(3):235–245. [PubMed] [Google Scholar]
  116. Linder D., Gartler S. M. Glucose-6-phosphate dehydrogenase mosaicism: utilization as a cell marker in the study of leiomyomas. Science. 1965 Oct 1;150(3692):67–69. doi: 10.1126/science.150.3692.67. [DOI] [PubMed] [Google Scholar]
  117. Lindner V., Reidy M. A. Proliferation of smooth muscle cells after vascular injury is inhibited by an antibody against basic fibroblast growth factor. Proc Natl Acad Sci U S A. 1991 May 1;88(9):3739–3743. doi: 10.1073/pnas.88.9.3739. [DOI] [PMC free article] [PubMed] [Google Scholar]
  118. Longcope C., Johnston C. C., Jr Androgen and estrogen dynamics in pre- and postmenopausal women: a comparison between smokers and nonsmokers. J Clin Endocrinol Metab. 1988 Aug;67(2):379–383. doi: 10.1210/jcem-67-2-379. [DOI] [PubMed] [Google Scholar]
  119. Lumbiganon P., Rugpao S., Phandhu-fung S., Laopaiboon M., Vudhikamraksa N., Werawatakul Y. Protective effect of depot-medroxyprogesterone acetate on surgically treated uterine leiomyomas: a multicentre case--control study. Br J Obstet Gynaecol. 1996 Sep;103(9):909–914. doi: 10.1111/j.1471-0528.1996.tb09911.x. [DOI] [PubMed] [Google Scholar]
  120. Lumsden M. A., West C. P., Baird D. T. Goserelin therapy before surgery for uterine fibroids. Lancet. 1987 Jan 3;1(8523):36–37. doi: 10.1016/s0140-6736(87)90718-5. [DOI] [PubMed] [Google Scholar]
  121. Lumsden M. A., West C. P., Baird D. T. Tamoxifen prolongs luteal phase in premenopausal women but has no effect on the size of uterine fibroids. Clin Endocrinol (Oxf) 1989 Sep;31(3):335–343. doi: 10.1111/j.1365-2265.1989.tb01257.x. [DOI] [PubMed] [Google Scholar]
  122. Lumsden M. A., West C. P., Bramley T., Rumgay L., Baird D. T. The binding of epidermal growth factor to the human uterus and leiomyomata in women rendered hypo-oestrogenic by continuous administration of an LHRH agonist. Br J Obstet Gynaecol. 1988 Dec;95(12):1299–1304. doi: 10.1111/j.1471-0528.1988.tb06821.x. [DOI] [PubMed] [Google Scholar]
  123. Lumsden M. A., West C. P., Hillier H., Baird D. T. Estrogenic action of tamoxifen in women treated with luteinizing hormone-releasing hormone agonists (goserelin)--lack of shrinkage of uterine fibroids. Fertil Steril. 1989 Dec;52(6):924–929. doi: 10.1016/s0015-0282(16)53153-7. [DOI] [PubMed] [Google Scholar]
  124. Luoto R., Kaprio J., Rutanen E. M., Taipale P., Perola M., Koskenvuo M. Heritability and risk factors of uterine fibroids--the Finnish Twin Cohort study. Maturitas. 2000 Nov 30;37(1):15–26. doi: 10.1016/s0378-5122(00)00160-2. [DOI] [PubMed] [Google Scholar]
  125. Lyons R. M., Moses H. L. Transforming growth factors and the regulation of cell proliferation. Eur J Biochem. 1990 Feb 14;187(3):467–473. doi: 10.1111/j.1432-1033.1990.tb15327.x. [DOI] [PubMed] [Google Scholar]
  126. MacMahon B., Trichopoulos D., Cole P., Brown J. Cigarette smoking and urinary estrogens. N Engl J Med. 1982 Oct 21;307(17):1062–1065. doi: 10.1056/NEJM198210213071707. [DOI] [PubMed] [Google Scholar]
  127. Maheux R., Lemay-Turcot L., Lemay A. Daily follicle-stimulating hormone, luteinizing hormone, estradiol, and progesterone in ten women harboring uterine leiomyomas. Fertil Steril. 1986 Aug;46(2):205–208. doi: 10.1016/s0015-0282(16)49512-9. [DOI] [PubMed] [Google Scholar]
  128. Mangrulkar R. S., Ono M., Ishikawa M., Takashima S., Klagsbrun M., Nowak R. A. Isolation and characterization of heparin-binding growth factors in human leiomyomas and normal myometrium. Biol Reprod. 1995 Sep;53(3):636–646. doi: 10.1095/biolreprod53.3.636. [DOI] [PubMed] [Google Scholar]
  129. Mark J., Havel G., Grepp C., Dahlenfors R., Wedell B. Cytogenetical observations in human benign uterine leiomyomas. Anticancer Res. 1988 Jul-Aug;8(4):621–626. [PubMed] [Google Scholar]
  130. Marshall L. M., Spiegelman D., Barbieri R. L., Goldman M. B., Manson J. E., Colditz G. A., Willett W. C., Hunter D. J. Variation in the incidence of uterine leiomyoma among premenopausal women by age and race. Obstet Gynecol. 1997 Dec;90(6):967–973. doi: 10.1016/s0029-7844(97)00534-6. [DOI] [PubMed] [Google Scholar]
  131. Marshall L. M., Spiegelman D., Goldman M. B., Manson J. E., Colditz G. A., Barbieri R. L., Stampfer M. J., Hunter D. J. A prospective study of reproductive factors and oral contraceptive use in relation to the risk of uterine leiomyomata. Fertil Steril. 1998 Sep;70(3):432–439. doi: 10.1016/s0015-0282(98)00208-8. [DOI] [PubMed] [Google Scholar]
  132. Marshall L. M., Spiegelman D., Manson J. E., Goldman M. B., Barbieri R. L., Stampfer M. J., Willett W. C., Hunter D. J. Risk of uterine leiomyomata among premenopausal women in relation to body size and cigarette smoking. Epidemiology. 1998 Sep;9(5):511–517. [PubMed] [Google Scholar]
  133. Martucci C. P., Fishman J. P450 enzymes of estrogen metabolism. Pharmacol Ther. 1993 Feb-Mar;57(2-3):237–257. doi: 10.1016/0163-7258(93)90057-k. [DOI] [PubMed] [Google Scholar]
  134. Marugo M., Centonze M., Bernasconi D., Fazzuoli L., Berta S., Giordano G. Estrogen and progesterone receptors in uterine leiomyomas. Acta Obstet Gynecol Scand. 1989;68(8):731–735. doi: 10.3109/00016348909006147. [DOI] [PubMed] [Google Scholar]
  135. Maruo T., Matsuo H., Samoto T., Shimomura Y., Kurachi O., Gao Z., Wang Y., Spitz I. M., Johansson E. Effects of progesterone on uterine leiomyoma growth and apoptosis. Steroids. 2000 Oct-Nov;65(10-11):585–592. doi: 10.1016/s0039-128x(00)00171-9. [DOI] [PubMed] [Google Scholar]
  136. Mashal R. D., Fejzo M. L., Friedman A. J., Mitchner N., Nowak R. A., Rein M. S., Morton C. C., Sklar J. Analysis of androgen receptor DNA reveals the independent clonal origins of uterine leiomyomata and the secondary nature of cytogenetic aberrations in the development of leiomyomata. Genes Chromosomes Cancer. 1994 Sep;11(1):1–6. doi: 10.1002/gcc.2870110102. [DOI] [PubMed] [Google Scholar]
  137. Maslar I. A., Riddick D. H. Prolactin production by human endometrium during the normal menstrual cycle. Am J Obstet Gynecol. 1979 Nov 15;135(6):751–754. doi: 10.1016/0002-9378(79)90386-7. [DOI] [PubMed] [Google Scholar]
  138. Massagué J. TGF-beta signal transduction. Annu Rev Biochem. 1998;67:753–791. doi: 10.1146/annurev.biochem.67.1.753. [DOI] [PubMed] [Google Scholar]
  139. McBride G. Benign but no longer forgotten--fibroids get their own conference. Lancet. 1999 Oct 23;354(9188):1450–1450. doi: 10.1016/S0140-6736(05)77589-9. [DOI] [PubMed] [Google Scholar]
  140. McCluggage W. G., Varma M., Weir P., Bharucha H. Uterine leiomyosarcoma in patient receiving tamoxifen therapy. Acta Obstet Gynecol Scand. 1996 Jul;75(6):593–595. doi: 10.3109/00016349609054678. [DOI] [PubMed] [Google Scholar]
  141. Meadows R. Growing pains. Environ Health Perspect. 1996 Feb;104(2):146–149. doi: 10.1289/ehp.104-1469278. [DOI] [PMC free article] [PubMed] [Google Scholar]
  142. Meloni A. M., Surti U., Contento A. M., Davare J., Sandberg A. A. Uterine leiomyomas: cytogenetic and histologic profile. Obstet Gynecol. 1992 Aug;80(2):209–217. [PubMed] [Google Scholar]
  143. Michnovicz J. J., Hershcopf R. J., Naganuma H., Bradlow H. L., Fishman J. Increased 2-hydroxylation of estradiol as a possible mechanism for the anti-estrogenic effect of cigarette smoking. N Engl J Med. 1986 Nov 20;315(21):1305–1309. doi: 10.1056/NEJM198611203152101. [DOI] [PubMed] [Google Scholar]
  144. Miyazono K. Positive and negative regulation of TGF-beta signaling. J Cell Sci. 2000 Apr;113(Pt 7):1101–1109. doi: 10.1242/jcs.113.7.1101. [DOI] [PubMed] [Google Scholar]
  145. Mosselman S., Polman J., Dijkema R. ER beta: identification and characterization of a novel human estrogen receptor. FEBS Lett. 1996 Aug 19;392(1):49–53. doi: 10.1016/0014-5793(96)00782-x. [DOI] [PubMed] [Google Scholar]
  146. Murphy A. A., Kettel L. M., Morales A. J., Roberts V. J., Yen S. S. Regression of uterine leiomyomata in response to the antiprogesterone RU 486. J Clin Endocrinol Metab. 1993 Feb;76(2):513–517. doi: 10.1210/jcem.76.2.8432797. [DOI] [PubMed] [Google Scholar]
  147. Neufeld G., Cohen T., Gengrinovitch S., Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 1999 Jan;13(1):9–22. [PubMed] [Google Scholar]
  148. Newbold R. R., DiAugustine R. P., Risinger J. I., Everitt J. I., Walmer D. K., Parrott E. C., Dixon D. Advances in uterine leiomyoma research: conference overview, summary, and future research recommendations. Environ Health Perspect. 2000 Oct;108 (Suppl 5):769–773. doi: 10.1289/ehp.00108s5769. [DOI] [PubMed] [Google Scholar]
  149. Newbold R. Cellular and molecular effects of developmental exposure to diethylstilbestrol: implications for other environmental estrogens. Environ Health Perspect. 1995 Oct;103 (Suppl 7):83–87. doi: 10.1289/ehp.95103s783. [DOI] [PMC free article] [PubMed] [Google Scholar]
  150. Newbold Retha R., Moore Alicia B., Dixon Darlene. Characterization of uterine leiomyomas in CD-1 mice following developmental exposure to diethylstilbestrol (DES). Toxicol Pathol. 2002 Sep-Oct;30(5):611–616. doi: 10.1080/01926230290105839. [DOI] [PubMed] [Google Scholar]
  151. Nibert M., Heim S. Uterine leiomyoma cytogenetics. Genes Chromosomes Cancer. 1990 May;2(1):3–13. doi: 10.1002/gcc.2870020103. [DOI] [PubMed] [Google Scholar]
  152. Nikov G. N., Hopkins N. E., Boue S., Alworth W. L. Interactions of dietary estrogens with human estrogen receptors and the effect on estrogen receptor-estrogen response element complex formation. Environ Health Perspect. 2000 Sep;108(9):867–872. doi: 10.1289/ehp.00108867. [DOI] [PMC free article] [PubMed] [Google Scholar]
  153. Nisolle M., Gillerot S., Casanas-Roux F., Squifflet J., Berliere M., Donnez J. Immunohistochemical study of the proliferation index, oestrogen receptors and progesterone receptors A and B in leiomyomata and normal myometrium during the menstrual cycle and under gonadotrophin-releasing hormone agonist therapy. Hum Reprod. 1999 Nov;14(11):2844–2850. doi: 10.1093/humrep/14.11.2844. [DOI] [PubMed] [Google Scholar]
  154. Nissley P., Lopaczynski W. Insulin-like growth factor receptors. Growth Factors. 1991;5(1):29–43. doi: 10.3109/08977199109000269. [DOI] [PubMed] [Google Scholar]
  155. Nowak R. A. Fibroids: pathophysiology and current medical treatment. Baillieres Best Pract Res Clin Obstet Gynaecol. 1999 Jun;13(2):223–238. doi: 10.1053/beog.1999.0019. [DOI] [PubMed] [Google Scholar]
  156. Nowak R. A., Mora S., Diehl T., Rhoades A. R., Stewart E. A. Prolactin is an autocrine or paracrine growth factor for human myometrial and leiomyoma cells. Gynecol Obstet Invest. 1999;48(2):127–132. doi: 10.1159/000010154. [DOI] [PubMed] [Google Scholar]
  157. Oates A. J., Schumaker L. M., Jenkins S. B., Pearce A. A., DaCosta S. A., Arun B., Ellis M. J. The mannose 6-phosphate/insulin-like growth factor 2 receptor (M6P/IGF2R), a putative breast tumor suppressor gene. Breast Cancer Res Treat. 1998 Feb;47(3):269–281. doi: 10.1023/a:1005959218524. [DOI] [PubMed] [Google Scholar]
  158. Otsuka H., Shinohara M., Kashimura M., Yoshida K., Okamura Y. A comparative study of the estrogen receptor ratio in myometrium and uterine leiomyomas. Int J Gynaecol Obstet. 1989 Jun;29(2):189–194. doi: 10.1016/0020-7292(89)90853-9. [DOI] [PubMed] [Google Scholar]
  159. Otubu J. A., Buttram V. C., Besch N. F., Besch P. K. Unconjugated steroids in leiomyomas and tumor-bearing myometrium. Am J Obstet Gynecol. 1982 May 15;143(2):130–133. doi: 10.1016/0002-9378(82)90640-8. [DOI] [PubMed] [Google Scholar]
  160. Ozisik Y. Y., Meloni A. M., Powell M., Surti U., Sandberg A. A. Chromosome 7 biclonality in uterine leiomyoma. Cancer Genet Cytogenet. 1993 May;67(1):59–64. doi: 10.1016/0165-4608(93)90045-n. [DOI] [PubMed] [Google Scholar]
  161. Ozisik Y. Y., Meloni A. M., Surti U., Sandberg A. A. Deletion 7q22 in uterine leiomyoma. A cytogenetic review. Cancer Genet Cytogenet. 1993 Nov;71(1):1–6. doi: 10.1016/0165-4608(93)90195-r. [DOI] [PubMed] [Google Scholar]
  162. Packenham J. P., du Manoir S., Schrock E., Risinger J. I., Dixon D., Denz D. N., Evans J. A., Berchuck A., Barrett J. C., Devereux T. R. Analysis of genetic alterations in uterine leiomyomas and leiomyosarcomas by comparative genomic hybridization. Mol Carcinog. 1997 Aug;19(4):273–279. doi: 10.1002/(sici)1098-2744(199708)19:4<273::aid-mc9>3.0.co;2-d. [DOI] [PubMed] [Google Scholar]
  163. Pandis N., Heim S., Bardi G., Flodérus U. M., Willén H., Mandahl N., Mitelman F. Parallel karyotypic evolution and tumor progression in uterine leiomyoma. Genes Chromosomes Cancer. 1990 Nov;2(4):311–317. doi: 10.1002/gcc.2870020409. [DOI] [PubMed] [Google Scholar]
  164. Parazzini F., La Vecchia C., Negri E., Cecchetti G., Fedele L. Epidemiologic characteristics of women with uterine fibroids: a case-control study. Obstet Gynecol. 1988 Dec;72(6):853–857. doi: 10.1097/00006250-198812000-00008. [DOI] [PubMed] [Google Scholar]
  165. Parazzini F., Negri E., La Vecchia C., Chatenoud L., Ricci E., Guarnerio P. Reproductive factors and risk of uterine fibroids. Epidemiology. 1996 Jul;7(4):440–442. doi: 10.1097/00001648-199607000-00018. [DOI] [PubMed] [Google Scholar]
  166. Parazzini F., Negri E., La Vecchia C., Fedele L., Rabaiotti M., Luchini L. Oral contraceptive use and risk of uterine fibroids. Obstet Gynecol. 1992 Mar;79(3):430–433. doi: 10.1097/00006250-199203000-00021. [DOI] [PubMed] [Google Scholar]
  167. Parazzini F., Negri E., La Vecchia C., Rabaiotti M., Luchini L., Villa A., Fedele L. Uterine myomas and smoking. Results from an Italian study. J Reprod Med. 1996 May;41(5):316–320. [PubMed] [Google Scholar]
  168. Pedeutour F., Quade B. J., Weremowicz S., Dal Cin P., Ali S., Morton C. C. Localization and expression of the human estrogen receptor beta gene in uterine leiomyomata. Genes Chromosomes Cancer. 1998 Dec;23(4):361–366. doi: 10.1002/(sici)1098-2264(199812)23:4<361::aid-gcc12>3.0.co;2-4. [DOI] [PubMed] [Google Scholar]
  169. Pledger W. J., Stiles C. D., Antoniades H. N., Scher C. D. An ordered sequence of events is required before BALB/c-3T3 cells become committed to DNA synthesis. Proc Natl Acad Sci U S A. 1978 Jun;75(6):2839–2843. doi: 10.1073/pnas.75.6.2839. [DOI] [PMC free article] [PubMed] [Google Scholar]
  170. Polatti F., Viazzo F., Colleoni R., Nappi R. E. Uterine myoma in postmenopause: a comparison between two therapeutic schedules of HRT. Maturitas. 2000 Nov 30;37(1):27–32. doi: 10.1016/s0378-5122(00)00159-6. [DOI] [PubMed] [Google Scholar]
  171. Pollow K., Geilfuss J., Boquoi E., Pollow B. Estrogen and progesterone binding proteins in normal human myometrium and leiomyoma tissue. J Clin Chem Clin Biochem. 1978 Sep;16(9):503–511. doi: 10.1515/cclm.1978.16.9.503. [DOI] [PubMed] [Google Scholar]
  172. Pollow K., Sinnecker G., Boquoi E., Pollow B. In vitro conversion of estradiol-17beta into estrone in normal human myometrium and leiomyoma. J Clin Chem Clin Biochem. 1978 Sep;16(9):493–502. doi: 10.1515/cclm.1978.16.9.493. [DOI] [PubMed] [Google Scholar]
  173. Prentice R., Thompson D., Clifford C., Gorbach S., Goldin B., Byar D. Dietary fat reduction and plasma estradiol concentration in healthy postmenopausal women. The Women's Health Trial Study Group. J Natl Cancer Inst. 1990 Jan 17;82(2):129–134. doi: 10.1093/jnci/82.2.129. [DOI] [PubMed] [Google Scholar]
  174. Presta M. Sex hormones modulate the synthesis of basic fibroblast growth factor in human endometrial adenocarcinoma cells: implications for the neovascularization of normal and neoplastic endometrium. J Cell Physiol. 1988 Dec;137(3):593–597. doi: 10.1002/jcp.1041370329. [DOI] [PubMed] [Google Scholar]
  175. Pusztai L., Lewis C. E., Lorenzen J., McGee J. O. Growth factors: regulation of normal and neoplastic growth. J Pathol. 1993 Feb;169(2):191–201. doi: 10.1002/path.1711690204. [DOI] [PubMed] [Google Scholar]
  176. Puukka M. J., Kontula K. K., Kauppila A. J., Janne O. A., Vihko R. K. Estrogen receptor in human myoma tissue. Mol Cell Endocrinol. 1976 Nov;6(1):35–44. doi: 10.1016/0303-7207(76)90042-3. [DOI] [PubMed] [Google Scholar]
  177. Ratech H., Stewart M. E. Uterine leiomyomas, serum cholesterol, and oral contraceptives. A preliminary study of epidemiologic differences in Los Angeles, California and Albany, New York. Diagn Gynecol Obstet. 1982 Spring;4(1):21–24. [PubMed] [Google Scholar]
  178. Ratner H. Risk factors for uterine fibroids: reduced risk associated with oral contraceptives. Br Med J (Clin Res Ed) 1986 Oct 18;293(6553):1027–1027. doi: 10.1136/bmj.293.6553.1027-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  179. Ravindran J., Kumaraguruparan M. A survey of hysterectomy patterns in Malaysia. Med J Malaysia. 1998 Sep;53(3):263–271. [PubMed] [Google Scholar]
  180. Reed W. B., Walker R., Horowitz R. Cutaneous leiomyomata with uterine leiomyomata. Acta Derm Venereol. 1973;53(5):409–416. [PubMed] [Google Scholar]
  181. Reeves R. Structure and function of the HMGI(Y) family of architectural transcription factors. Environ Health Perspect. 2000 Oct;108 (Suppl 5):803–809. doi: 10.1289/ehp.00108s5803. [DOI] [PubMed] [Google Scholar]
  182. Rein M. S. Advances in uterine leiomyoma research: the progesterone hypothesis. Environ Health Perspect. 2000 Oct;108 (Suppl 5):791–793. doi: 10.1289/ehp.00108s5791. [DOI] [PubMed] [Google Scholar]
  183. Rein M. S., Barbieri R. L., Friedman A. J. Progesterone: a critical role in the pathogenesis of uterine myomas. Am J Obstet Gynecol. 1995 Jan;172(1 Pt 1):14–18. doi: 10.1016/0002-9378(95)90077-2. [DOI] [PubMed] [Google Scholar]
  184. Rein M. S., Friedman A. J., Heffner L. J. Decreased prolactin secretion by explant cultures of fibroids from women treated with a gonadotropin-releasing hormone agonist. J Clin Endocrinol Metab. 1990 Jun;70(6):1554–1558. doi: 10.1210/jcem-70-6-1554. [DOI] [PubMed] [Google Scholar]
  185. Rein M. S., Friedman A. J., Pandian M. R., Heffner L. J. The secretion of insulin-like growth factors I and II by explant cultures of fibroids and myometrium from women treated with a gonadotropin-releasing hormone agonist. Obstet Gynecol. 1990 Sep;76(3 Pt 1):388–394. [PubMed] [Google Scholar]
  186. Rein M. S., Friedman A. J., Stuart J. M., MacLaughlin D. T. Fibroid and myometrial steroid receptors in women treated with gonadotropin-releasing hormone agonist leuprolide acetate. Fertil Steril. 1990 Jun;53(6):1018–1023. [PubMed] [Google Scholar]
  187. Rein M. S., Powell W. L., Walters F. C., Weremowicz S., Cantor R. M., Barbieri R. L., Morton C. C. Cytogenetic abnormalities in uterine myomas are associated with myoma size. Mol Hum Reprod. 1998 Jan;4(1):83–86. doi: 10.1093/molehr/4.1.83. [DOI] [PubMed] [Google Scholar]
  188. Reynolds L. P., Kirsch J. D., Kraft K. C., Redmer D. A. Time-course of the uterine response to estradiol-17beta in ovariectomized ewes: expression of angiogenic factors. Biol Reprod. 1998 Sep;59(3):613–620. doi: 10.1095/biolreprod59.3.613. [DOI] [PubMed] [Google Scholar]
  189. Rice M. C., Smith S. T., Bullrich F., Havre P., Kmiec E. B. Isolation of human and mouse genes based on homology to REC2, a recombinational repair gene from the fungus Ustilago maydis. Proc Natl Acad Sci U S A. 1997 Jul 8;94(14):7417–7422. doi: 10.1073/pnas.94.14.7417. [DOI] [PMC free article] [PubMed] [Google Scholar]
  190. Richards P. A., Tiltman A. J. Anatomical variation of the oestrogen receptor in the non-neoplastic myometrium of fibromyomatous uteri. Virchows Arch. 1996 Aug;428(6):347–351. doi: 10.1007/BF00202201. [DOI] [PubMed] [Google Scholar]
  191. Rider V., Carlone D. L., Foster R. T. Oestrogen and progesterone control basic fibroblast growth factor mRNA in the rat uterus. J Endocrinol. 1997 Jul;154(1):75–84. doi: 10.1677/joe.0.1540075. [DOI] [PubMed] [Google Scholar]
  192. Robboy S. J., Bentley R. C., Butnor K., Anderson M. C. Pathology and pathophysiology of uterine smooth-muscle tumors. Environ Health Perspect. 2000 Oct;108 (Suppl 5):779–784. doi: 10.1289/ehp.00108s5779. [DOI] [PubMed] [Google Scholar]
  193. Rosati P., Exacoustòs C., Mancuso S. Longitudinal evaluation of uterine myoma growth during pregnancy. A sonographic study. J Ultrasound Med. 1992 Oct;11(10):511–515. doi: 10.7863/jum.1992.11.10.511. [DOI] [PubMed] [Google Scholar]
  194. Rose D. P., Boyar A. P., Cohen C., Strong L. E. Effect of a low-fat diet on hormone levels in women with cystic breast disease. I. Serum steroids and gonadotropins. J Natl Cancer Inst. 1987 Apr;78(4):623–626. [PubMed] [Google Scholar]
  195. Rose D. P., Goldman M., Connolly J. M., Strong L. E. High-fiber diet reduces serum estrogen concentrations in premenopausal women. Am J Clin Nutr. 1991 Sep;54(3):520–525. doi: 10.1093/ajcn/54.3.520. [DOI] [PubMed] [Google Scholar]
  196. Rosenthal S. M., Hsiao D., Silverman L. A. An insulin-like growth factor-II (IGF-II) analog with highly selective affinity for IGF-II receptors stimulates differentiation, but not IGF-I receptor down-regulation in muscle cells. Endocrinology. 1994 Jul;135(1):38–44. doi: 10.1210/endo.135.1.8013373. [DOI] [PubMed] [Google Scholar]
  197. Ross R. K., Pike M. C., Vessey M. P., Bull D., Yeates D., Casagrande J. T. Risk factors for uterine fibroids: reduced risk associated with oral contraceptives. Br Med J (Clin Res Ed) 1986 Aug 9;293(6543):359–362. doi: 10.1136/bmj.293.6543.359. [DOI] [PMC free article] [PubMed] [Google Scholar]
  198. Rustin P., Bourgeron T., Parfait B., Chretien D., Munnich A., Rötig A. Inborn errors of the Krebs cycle: a group of unusual mitochondrial diseases in human. Biochim Biophys Acta. 1997 Aug 22;1361(2):185–197. doi: 10.1016/s0925-4439(97)00035-5. [DOI] [PubMed] [Google Scholar]
  199. Sabatini R., Di Fazio F., Loizzi P. Uterine leiomyosarcoma in a postmenopausal woman treated with tamoxifen: case report. Eur J Gynaecol Oncol. 1999;20(4):327–328. [PubMed] [Google Scholar]
  200. Sadan O., van Iddekinge B., van Gelderen C. J., Savage N., Becker P. J., van der Walt L. A., Robinson M. Oestrogen and progesterone receptor concentrations in leiomyoma and normal myometrium. Ann Clin Biochem. 1987 May;24(Pt 3):263–267. doi: 10.1177/000456328702400304. [DOI] [PubMed] [Google Scholar]
  201. Samadi A. R., Lee N. C., Flanders W. D., Boring J. R., 3rd, Parris E. B. Risk factors for self-reported uterine fibroids: a case-control study. Am J Public Health. 1996 Jun;86(6):858–862. doi: 10.2105/ajph.86.6.858. [DOI] [PMC free article] [PubMed] [Google Scholar]
  202. Sato F., Miyake H., Nishi M., Kudo R. Fertility and uterine size among Asian women undergoing hysterectomy for leiomyomas. Int J Fertil Womens Med. 2000 Jan-Feb;45(1):34–37. [PubMed] [Google Scholar]
  203. Sato F., Miyake H., Nishi M., Mori M., Kudo R. Early normal menstrual cycle pattern and the development of uterine leiomyomas. J Womens Health Gend Based Med. 2000 Apr;9(3):299–302. doi: 10.1089/152460900318489. [DOI] [PubMed] [Google Scholar]
  204. Sato F., Nishi M., Kudo R., Miyake H. Body fat distribution and uterine leiomyomas. J Epidemiol. 1998 Aug;8(3):176–180. doi: 10.2188/jea.8.176. [DOI] [PubMed] [Google Scholar]
  205. Sauro M. D., Zorn N. E. Prolactin induces proliferation of vascular smooth muscle cells through a protein kinase C-dependent mechanism. J Cell Physiol. 1991 Jul;148(1):133–138. doi: 10.1002/jcp.1041480116. [DOI] [PubMed] [Google Scholar]
  206. Saxena S. P., Khare C., Farooq A., Murugesan K., Buckshee K., Chandra J. DDT and its metabolites in leiomyomatous and normal human uterine tissue. Arch Toxicol. 1987 Apr;59(6):453–455. doi: 10.1007/BF00316214. [DOI] [PubMed] [Google Scholar]
  207. Schmidt-Gollwitzer M., Eiletz J., Genz T., Pollow K. Determination of estradiol, estrone, and progesterone in serum and myometrium: correlation with the content of sex steroid receptors and 17 beta-hydroxysteroid dehydrogenase activity throughout the menstrual cycle. J Clin Endocrinol Metab. 1979 Sep;49(3):370–376. doi: 10.1210/jcem-49-3-370. [DOI] [PubMed] [Google Scholar]
  208. Schneider J., Bradlow H. L., Strain G., Levin J., Anderson K., Fishman J. Effects of obesity on estradiol metabolism: decreased formation of nonuterotropic metabolites. J Clin Endocrinol Metab. 1983 May;56(5):973–978. doi: 10.1210/jcem-56-5-973. [DOI] [PubMed] [Google Scholar]
  209. Schoenmakers E. F., Huysmans C., Van de Ven W. J. Allelic knockout of novel splice variants of human recombination repair gene RAD51B in t(12;14) uterine leiomyomas. Cancer Res. 1999 Jan 1;59(1):19–23. [PubMed] [Google Scholar]
  210. Schwartz S. M., Marshall L. M., Baird D. D. Epidemiologic contributions to understanding the etiology of uterine leiomyomata. Environ Health Perspect. 2000 Oct;108 (Suppl 5):821–827. doi: 10.1289/ehp.00108s5821. [DOI] [PubMed] [Google Scholar]
  211. Sener A. B., Seçkin N. C., Ozmen S., Gökmen O., Doğu N., Ekici E. The effects of hormone replacement therapy on uterine fibroids in postmenopausal women. Fertil Steril. 1996 Feb;65(2):354–357. doi: 10.1016/s0015-0282(16)58098-4. [DOI] [PubMed] [Google Scholar]
  212. Shaw R. W. Mechanism of LHRH analogue action in uterine fibroids. Horm Res. 1989;32 (Suppl 1):150–153. doi: 10.1159/000181332. [DOI] [PubMed] [Google Scholar]
  213. Shikora S. A., Niloff J. M., Bistrian B. R., Forse R. A., Blackburn G. L. Relationship between obesity and uterine leiomyomata. Nutrition. 1991 Jul-Aug;7(4):251–255. [PubMed] [Google Scholar]
  214. Shinohara A., Ogawa H., Ogawa T. Rad51 protein involved in repair and recombination in S. cerevisiae is a RecA-like protein. Cell. 1992 May 1;69(3):457–470. doi: 10.1016/0092-8674(92)90447-k. [DOI] [PubMed] [Google Scholar]
  215. Shu Z., Smith S., Wang L., Rice M. C., Kmiec E. B. Disruption of muREC2/RAD51L1 in mice results in early embryonic lethality which can Be partially rescued in a p53(-/-) background. Mol Cell Biol. 1999 Dec;19(12):8686–8693. doi: 10.1128/mcb.19.12.8686. [DOI] [PMC free article] [PubMed] [Google Scholar]
  216. Silva E. G., Tornos C. S., Follen-Mitchell M. Malignant neoplasms of the uterine corpus in patients treated for breast carcinoma: the effects of tamoxifen. Int J Gynecol Pathol. 1994 Jul;13(3):248–258. doi: 10.1097/00004347-199407000-00009. [DOI] [PubMed] [Google Scholar]
  217. Sonawane B. R. Chemical contaminants in human milk: an overview. Environ Health Perspect. 1995 Sep;103 (Suppl 6):197–205. doi: 10.1289/ehp.95103s6197. [DOI] [PMC free article] [PubMed] [Google Scholar]
  218. Soules M. R., McCarty K. S., Jr Leiomyomas: steroid receptor content. Variation within normal menstrual cycles. Am J Obstet Gynecol. 1982 May 1;143(1):6–11. doi: 10.1016/0002-9378(82)90676-7. [DOI] [PubMed] [Google Scholar]
  219. Spellacy W. N., Le Maire W. J., Buhi W. C., Birk S. A., Bradley B. A. Plasma growth hormone and estradiol levels in women with uterine myomas. Obstet Gynecol. 1972 Dec;40(6):829–834. [PubMed] [Google Scholar]
  220. Stellman S. D., Djordjevic M. V., Muscat J. E., Gong L., Bernstein D., Citron M. L., White A., Kemeny M., Busch E., Nafziger A. N. Relative abundance of organochlorine pesticides and polychlorinated biphenyls in adipose tissue and serum of women in Long Island, New York. Cancer Epidemiol Biomarkers Prev. 1998 Jun;7(6):489–496. [PubMed] [Google Scholar]
  221. Stewart E. A., Nowak R. A. Leiomyoma-related bleeding: a classic hypothesis updated for the molecular era. Hum Reprod Update. 1996 Jul-Aug;2(4):295–306. doi: 10.1093/humupd/2.4.295. [DOI] [PubMed] [Google Scholar]
  222. Stiles C. D., Capone G. T., Scher C. D., Antoniades H. N., Van Wyk J. J., Pledger W. J. Dual control of cell growth by somatomedins and platelet-derived growth factor. Proc Natl Acad Sci U S A. 1979 Mar;76(3):1279–1283. doi: 10.1073/pnas.76.3.1279. [DOI] [PMC free article] [PubMed] [Google Scholar]
  223. Stovall T. G., Ling F. W., Henry L. C., Woodruff M. R. A randomized trial evaluating leuprolide acetate before hysterectomy as treatment for leiomyomas. Am J Obstet Gynecol. 1991 Jun;164(6 Pt 1):1420–1425. doi: 10.1016/0002-9378(91)91419-w. [DOI] [PubMed] [Google Scholar]
  224. Strawn E. Y., Jr, Novy M. J., Burry K. A., Bethea C. L. Insulin-like growth factor I promotes leiomyoma cell growth in vitro. Am J Obstet Gynecol. 1995 Jun;172(6):1837–1844. doi: 10.1016/0002-9378(95)91420-x. [DOI] [PubMed] [Google Scholar]
  225. Strobelt N., Ghidini A., Cavallone M., Pensabene I., Ceruti P., Vergani P. Natural history of uterine leiomyomas in pregnancy. J Ultrasound Med. 1994 May;13(5):399–401. doi: 10.7863/jum.1994.13.5.399. [DOI] [PubMed] [Google Scholar]
  226. Sumitani H., Shozu M., Segawa T., Murakami K., Yang H. J., Shimada K., Inoue M. In situ estrogen synthesized by aromatase P450 in uterine leiomyoma cells promotes cell growth probably via an autocrine/intracrine mechanism. Endocrinology. 2000 Oct;141(10):3852–3861. doi: 10.1210/endo.141.10.7719. [DOI] [PubMed] [Google Scholar]
  227. TIMONEN S., VAANANEN P. Uterine myoma. Some hormone assays. Acta Endocrinol (Copenh) 1959 Nov;32:384–390. doi: 10.1530/acta.0.xxxii0384. [DOI] [PubMed] [Google Scholar]
  228. Taioli E., Garte S. J., Trachman J., Garbers S., Sepkovic D. W., Osborne M. P., Mehl S., Bradlow H. L. Ethnic differences in estrogen metabolism in healthy women. J Natl Cancer Inst. 1996 May 1;88(9):617–617. doi: 10.1093/jnci/88.9.617. [DOI] [PubMed] [Google Scholar]
  229. Takahashi T., Eitzman B., Bossert N. L., Walmer D., Sparrow K., Flanders K. C., McLachlan J., Nelson K. G. Transforming growth factors beta 1, beta 2, and beta 3 messenger RNA and protein expression in mouse uterus and vagina during estrogen-induced growth: a comparison to other estrogen-regulated genes. Cell Growth Differ. 1994 Sep;5(9):919–935. [PubMed] [Google Scholar]
  230. Takahashi T., Nagai N., Oda H., Ohama K., Kamada N., Miyagawa K. Evidence for RAD51L1/HMGIC fusion in the pathogenesis of uterine leiomyoma. Genes Chromosomes Cancer. 2001 Feb;30(2):196–201. doi: 10.1002/1098-2264(2000)9999:9999<::aid-gcc1078>3.0.co;2-8. [DOI] [PubMed] [Google Scholar]
  231. Tamaya T., Fujimoto J., Okada H. Comparison of cellular levels of steroid receptors in uterine leiomyoma and myometrium. Acta Obstet Gynecol Scand. 1985;64(4):307–309. doi: 10.3109/00016348509155136. [DOI] [PubMed] [Google Scholar]
  232. Tamaya T., Motoyama T., Ohono Y., Ide N., Tsurusaki T., Okada H. Estradiol-17 beta-, progesterone and 5 alpha-dihydrotestosterone receptors of uterine myometrium and myoma in the human subject. J Steroid Biochem. 1979 Jun;10(6):615–622. doi: 10.1016/0022-4731(79)90513-2. [DOI] [PubMed] [Google Scholar]
  233. Tang X. M., Dou Q., Zhao Y., McLean F., Davis J., Chegini N. The expression of transforming growth factor-beta s and TGF-beta receptor mRNA and protein and the effect of TGF-beta s on human myometrial smooth muscle cells in vitro. Mol Hum Reprod. 1997 Mar;3(3):233–240. doi: 10.1093/molehr/3.3.233. [DOI] [PubMed] [Google Scholar]
  234. Taylor A. H., Al-Azzawi F. Immunolocalisation of oestrogen receptor beta in human tissues. J Mol Endocrinol. 2000 Feb;24(1):145–155. doi: 10.1677/jme.0.0240145. [DOI] [PubMed] [Google Scholar]
  235. Tham D. M., Gardner C. D., Haskell W. L. Clinical review 97: Potential health benefits of dietary phytoestrogens: a review of the clinical, epidemiological, and mechanistic evidence. J Clin Endocrinol Metab. 1998 Jul;83(7):2223–2235. doi: 10.1210/jcem.83.7.4752. [DOI] [PubMed] [Google Scholar]
  236. Thi M. T., Baulieu E. E., Milgrom E. Comparison of the characteristics and of the hormonal control of endometrial and myometrial progesterone receptors. J Endocrinol. 1975 Sep;66(3):349–356. doi: 10.1677/joe.0.0660349. [DOI] [PubMed] [Google Scholar]
  237. Thyresson H. N., Su W. P. Familial cutaneous leiomyomatosis. J Am Acad Dermatol. 1981 Apr;4(4):430–434. doi: 10.1016/s0190-9622(81)70042-2. [DOI] [PubMed] [Google Scholar]
  238. Tiltman A. J. The effect of progestins on the mitotic activity of uterine fibromyomas. Int J Gynecol Pathol. 1985;4(2):89–96. doi: 10.1097/00004347-198506000-00001. [DOI] [PubMed] [Google Scholar]
  239. Tomlinson Ian P. M., Alam N. Afrina, Rowan Andrew J., Barclay Ella, Jaeger Emma E. M., Kelsell David, Leigh Irene, Gorman Patricia, Lamlum Hanan, Rahman Shamima. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet. 2002 Feb 25;30(4):406–410. doi: 10.1038/ng849. [DOI] [PubMed] [Google Scholar]
  240. Tommola P., Pekonen F., Rutanen E. M. Binding of epidermal growth factor and insulin-like growth factor I in human myometrium and leiomyomata. Obstet Gynecol. 1989 Oct;74(4):658–662. [PubMed] [Google Scholar]
  241. Tomás E., Kauppila A., Blanco G., Apaja-Sarkkinen M., Laatikainen T. Comparison between the effects of tamoxifen and toremifene on the uterus in postmenopausal breast cancer patients. Gynecol Oncol. 1995 Nov;59(2):261–266. doi: 10.1006/gyno.1995.0019. [DOI] [PubMed] [Google Scholar]
  242. Townsend D. E., Sparkes R. S., Baluda M. C., McClelland G. Unicellular histogenesis of uterine leiomyomas as determined by electrophoresis by glucose-6-phosphate dehydrogenase. Am J Obstet Gynecol. 1970 Aug 15;107(8):1168–1173. doi: 10.1016/s0002-9378(15)30365-3. [DOI] [PubMed] [Google Scholar]
  243. Treloar S. A., Martin N. G., Dennerstein L., Raphael B., Heath A. C. Pathways to hysterectomy: insights from longitudinal twin research. Am J Obstet Gynecol. 1992 Jul;167(1):82–88. doi: 10.1016/s0002-9378(11)91632-9. [DOI] [PubMed] [Google Scholar]
  244. Troiano R. P., Flegal K. M. Overweight prevalence among youth in the United States: why so many different numbers? Int J Obes Relat Metab Disord. 1999 Mar;23 (Suppl 2):S22–S27. doi: 10.1038/sj.ijo.0800855. [DOI] [PubMed] [Google Scholar]
  245. Tseng L., Gurpide E. Induction of human endometrial estradiol dehydrogenase by progestins. Endocrinology. 1975 Oct;97(4):825–833. doi: 10.1210/endo-97-4-825. [DOI] [PubMed] [Google Scholar]
  246. Ugwumadu A. H., Harding K. Uterine leiomyomata and endometrial proliferation in postmenopausal women treated with the anti-oestrogen tamoxifen. Eur J Obstet Gynecol Reprod Biol. 1994 Apr;54(2):153–156. doi: 10.1016/0028-2243(94)90258-5. [DOI] [PubMed] [Google Scholar]
  247. Upadhyaya N. B., Doody M. C., Googe P. B. Histopathological changes in leiomyomata treated with leuprolide acetate. Fertil Steril. 1990 Nov;54(5):811–814. doi: 10.1016/s0015-0282(16)53937-5. [DOI] [PubMed] [Google Scholar]
  248. Van Itallie T. B. Health implications of overweight and obesity in the United States. Ann Intern Med. 1985 Dec;103(6 ):983–988. doi: 10.7326/0003-4819-103-6-983. [DOI] [PubMed] [Google Scholar]
  249. Van der Ven L. T., Roholl P. J., Gloudemans T., Van Buul-Offers S. C., Welters M. J., Bladergroen B. A., Faber J. A., Sussenbach J. S., Den Otter W. Expression of insulin-like growth factors (IGFs), their receptors and IGF binding protein-3 in normal, benign and malignant smooth muscle tissues. Br J Cancer. 1997;75(11):1631–1640. doi: 10.1038/bjc.1997.278. [DOI] [PMC free article] [PubMed] [Google Scholar]
  250. Vanni R., Van Roy N., Lecca U., Speleman F. Uterine leiomyoma cytogenetics. III. Interphase cytogenetic analysis of karyotypically normal uterine leiomyoma excludes possibility of undetected trisomy 12. Cancer Genet Cytogenet. 1992 Aug;62(1):40–42. doi: 10.1016/0165-4608(92)90035-7. [DOI] [PubMed] [Google Scholar]
  251. Velebil P., Wingo P. A., Xia Z., Wilcox L. S., Peterson H. B. Rate of hospitalization for gynecologic disorders among reproductive-age women in the United States. Obstet Gynecol. 1995 Nov;86(5):764–769. doi: 10.1016/0029-7844(95)00252-M. [DOI] [PubMed] [Google Scholar]
  252. Vij U., Murugesan K., Laumas K. R., Farooq A. Progestin and antiprogestin interactions with progesterone receptors in human myomas. Int J Gynaecol Obstet. 1990 Apr;31(4):347–353. doi: 10.1016/0020-7292(90)90913-6. [DOI] [PubMed] [Google Scholar]
  253. Vikhlyaeva E. M., Khodzhaeva Z. S., Fantschenko N. D. Familial predisposition to uterine leiomyomas. Int J Gynaecol Obstet. 1995 Nov;51(2):127–131. doi: 10.1016/0020-7292(95)02533-i. [DOI] [PubMed] [Google Scholar]
  254. Viville B., Charnock-Jones D. S., Sharkey A. M., Wetzka B., Smith S. K. Distribution of the A and B forms of the progesterone receptor messenger ribonucleic acid and protein in uterine leiomyomata and adjacent myometrium. Hum Reprod. 1997 Apr;12(4):815–822. doi: 10.1093/humrep/12.4.815. [DOI] [PubMed] [Google Scholar]
  255. Vogelstein B., Fearon E. R., Hamilton S. R., Feinberg A. P. Use of restriction fragment length polymorphisms to determine the clonal origin of human tumors. Science. 1985 Feb 8;227(4687):642–645. doi: 10.1126/science.2982210. [DOI] [PubMed] [Google Scholar]
  256. Vogelstein B., Fearon E. R., Hamilton S. R., Preisinger A. C., Willard H. F., Michelson A. M., Riggs A. D., Orkin S. H. Clonal analysis using recombinant DNA probes from the X-chromosome. Cancer Res. 1987 Sep 15;47(18):4806–4813. [PubMed] [Google Scholar]
  257. Vollenhoven B. J., Herington A. C., Healy D. L. Messenger ribonucleic acid expression of the insulin-like growth factors and their binding proteins in uterine fibroids and myometrium. J Clin Endocrinol Metab. 1993 May;76(5):1106–1110. doi: 10.1210/jcem.76.5.7684390. [DOI] [PubMed] [Google Scholar]
  258. Vollenhoven B. J., Lawrence A. S., Healy D. L. Uterine fibroids: a clinical review. Br J Obstet Gynaecol. 1990 Apr;97(4):285–298. doi: 10.1111/j.1471-0528.1990.tb01804.x. [DOI] [PubMed] [Google Scholar]
  259. Vollenhoven B. J., Pearce P., Herington A. C., Healy D. L. Steroid receptor binding and messenger RNA expression in fibroids from untreated and gonadotrophin-releasing hormone agonist pretreated women. Clin Endocrinol (Oxf) 1994 Apr;40(4):537–544. doi: 10.1111/j.1365-2265.1994.tb02495.x. [DOI] [PubMed] [Google Scholar]
  260. Vu K., Greenspan D. L., Wu T. C., Zacur H. A., Kurman R. J. Cellular proliferation, estrogen receptor, progesterone receptor, and bcl-2 expression in GnRH agonist-treated uterine leiomyomas. Hum Pathol. 1998 Apr;29(4):359–363. doi: 10.1016/s0046-8177(98)90116-2. [DOI] [PubMed] [Google Scholar]
  261. Wack J. T., Rodin J. Smoking and its effects on body weight and the systems of caloric regulation. Am J Clin Nutr. 1982 Feb;35(2):366–380. doi: 10.1093/ajcn/35.2.366. [DOI] [PubMed] [Google Scholar]
  262. Walters C. A., Daly D. C., Chapitis J., Kuslis S. T., Prior J. C., Kusmik W. F., Riddick D. H. Human myometrium: a new potential source of prolactin. Am J Obstet Gynecol. 1983 Nov 15;147(6):639–644. doi: 10.1016/0002-9378(83)90441-6. [DOI] [PubMed] [Google Scholar]
  263. Westhoff C., Gentile G., Lee J., Zacur H., Helbig D. Predictors of ovarian steroid secretion in reproductive-age women. Am J Epidemiol. 1996 Aug 15;144(4):381–388. doi: 10.1093/oxfordjournals.aje.a008939. [DOI] [PubMed] [Google Scholar]
  264. Wilcox L. S., Koonin L. M., Pokras R., Strauss L. T., Xia Z., Peterson H. B. Hysterectomy in the United States, 1988-1990. Obstet Gynecol. 1994 Apr;83(4):549–555. doi: 10.1097/00006250-199404000-00011. [DOI] [PubMed] [Google Scholar]
  265. Wilson E. A., Yang F., Rees E. D. Estradiol and progesterone binding in uterine leiomyomata and in normal uterine tissues. Obstet Gynecol. 1980 Jan;55(1):20–24. [PubMed] [Google Scholar]
  266. Woods M. N., Barnett J. B., Spiegelman D., Trail N., Hertzmark E., Longcope C., Gorbach S. L. Hormone levels during dietary changes in premenopausal African-American women. J Natl Cancer Inst. 1996 Oct 2;88(19):1369–1374. doi: 10.1093/jnci/88.19.1369. [DOI] [PubMed] [Google Scholar]
  267. Wyshak G., Frisch R. E., Albright N. L., Albright T. E., Schiff I. Lower prevalence of benign diseases of the breast and benign tumours of the reproductive system among former college athletes compared to non-athletes. Br J Cancer. 1986 Nov;54(5):841–845. doi: 10.1038/bjc.1986.249. [DOI] [PMC free article] [PubMed] [Google Scholar]
  268. Yamamoto T., Takamori K., Okada H. Estrogen biosynthesis in leiomyoma and myometrium of the uterus. Horm Metab Res. 1984 Dec;16(12):678–679. doi: 10.1055/s-2007-1014884. [DOI] [PubMed] [Google Scholar]
  269. Yeh J., Rein M., Nowak R. Presence of messenger ribonucleic acid for epidermal growth factor (EGF) and EGF receptor demonstrable in monolayer cell cultures of myometria and leiomyomata. Fertil Steril. 1991 Nov;56(5):997–1000. doi: 10.1016/s0015-0282(16)54681-0. [DOI] [PubMed] [Google Scholar]
  270. Ylöstalo P., Granberg S., Bäckström A. C., Hirsjärvi-Lahti T. Uterine findings by transvaginal sonography during percutaneous estrogen treatment in postmenopausal women. Maturitas. 1996 Apr;23(3):313–317. doi: 10.1016/0378-5122(96)00993-0. [DOI] [PubMed] [Google Scholar]
  271. Yu H., Berkel H. Insulin-like growth factors and cancer. J La State Med Soc. 1999 Apr;151(4):218–223. [PubMed] [Google Scholar]
  272. Zhu B. T., Conney A. H. Functional role of estrogen metabolism in target cells: review and perspectives. Carcinogenesis. 1998 Jan;19(1):1–27. doi: 10.1093/carcin/19.1.1. [DOI] [PubMed] [Google Scholar]
  273. Zumoff B., Miller L., Levit C. D., Miller E. H., Heinz U., Kalin M., Denman H., Jandorek R., Rosenfeld R. S. The effect of smoking on serum progesterone, estradiol, and luteinizing hormone levels over a menstrual cycle in normal women. Steroids. 1990 Nov;55(11):507–511. doi: 10.1016/0039-128x(90)90089-t. [DOI] [PubMed] [Google Scholar]
  274. de Aloysio D., Altieri P., Penacchioni P., Salgarello M., Ventura V. Bleeding patterns in recent postmenopausal outpatients with uterine myomas: comparison between two regimens of HRT. Maturitas. 1998 Jun 17;29(3):261–264. doi: 10.1016/s0378-5122(98)00014-0. [DOI] [PubMed] [Google Scholar]
  275. van der Heijden O., Chiu H. C., Park T. C., Takahashi H., LiVolsi V. A., Risinger J. I., Barrett J. C., Berchuck A., Evans A. C., Behbakht K. Allelotype analysis of uterine leiomyoma: localization of a potential tumor suppressor gene to a 4-cM region of chromosome 7q. Mol Carcinog. 1998 Dec;23(4):243–247. doi: 10.1002/(sici)1098-2744(199812)23:4<243::aid-mc7>3.0.co;2-e. [DOI] [PubMed] [Google Scholar]

Articles from Environmental Health Perspectives are provided here courtesy of National Institute of Environmental Health Sciences

RESOURCES